Skip to main content

Advertisement

SpringerLink
Log in

mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience

  • Original Article
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

Abstract

Background

Encapsulating peritoneal sclerosis (EPS) is a serious complication in patients on peritoneal dialysis (PD) causing intestinal obstruction. Two different forms of EPS are reported: the classical one observed in patients on PD, and post-transplantation EPS (PostTx-EPS). The first-line therapy of classical and PostTx-EPS remains surgical treatment, but for both the complication rate and mortality are high. Recently, a few cases of EPS were successfully treated with inhibitors of mammalian target of rapamycin (mTORi). The aim of this study was to evaluate PostTx-EPS outcome in our patients, focusing on the potential benefit of mTORi treatment.

Methods

We performed a retrospective analysis on 1,048 kidney transplanted patients at our center between 11/2001 and 12/2011.

Results

In the 226 patients treated with PD at any time before grafting, we found 10 cases of PostTx-EPS (prevalence 4.4 %). The mean age was 54.9 years (26–69), with a mean time on PD of 83.1 months (33–156). The interval between kidney transplant and EPS diagnosis was 10.5 months (4–18.9). Five of the ten patients were treated after the diagnosis with mTORi, with a favorable outcome in 4/5 cases. This result was substantially independent of surgical and steroid therapy, performed in 9/10 and 10/10 patients respectively.

Conclusion

EPS is a serious complication but susceptible to improvement if early diagnosed. mTORi represent a useful option for EPS treatment. We too suggest adopting an immunosuppressive protocol based on mTORi, mycophenolate mofetil and steroids in order to prevent PostTx-EPS in transplanted patients at high risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kawaguchi Y, Kawanishi H, Minujais S et al (2000) International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management Peritoneal Dialysis. Encapsulating peritoneal sclerosis. Perit Dial Int 20:S43–S55

    PubMed  Google Scholar 

  2. Rigby RJ, Hawley CM (1998) Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 13:154–159

    Article  CAS  PubMed  Google Scholar 

  3. Summers AM, Clancy MJ, Syed F et al (2005) Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 68:2381–2388

    Article  PubMed  Google Scholar 

  4. Kawanishi H, Shintaku S, Moriishi M et al (2011) Seventeen years’ experience of surgical option for encapsulating peritoneal sclerosis. Adv Perit Dial 27:53–58

    PubMed  Google Scholar 

  5. Kawanishi H (2012) Surgical and medical treatments of encapsulating peritoneal sclerosis. Contrib Nephrol 177:38–47

    Article  PubMed  Google Scholar 

  6. Habib SM, Korte MR, Betjes MG (2013) Lower mortality and inflammation from posttransplantation encapsulating peritoneal sclerosis compared to the classical form. Am J Nephrol 37:223–230

    Article  PubMed  Google Scholar 

  7. Korte MR, Yo M, Betjes MG et al (2007) Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 22:2412–2414

    Article  PubMed  Google Scholar 

  8. Korte MR, Habib SM, Lingsma H et al (2011) Posttransplantation encapsulating peritoneal sclerosis contributes significantly to mortality after kidney transplantation. Am J Transplant 11:599–605

    Article  CAS  PubMed  Google Scholar 

  9. Fieren MW, Betjes MG, Korte MR et al (2007) Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 27:619–624

    PubMed  Google Scholar 

  10. Garosi G, Mancianti N, Corciulo R et al (2013) Encapsulating peritoneal sclerosis. J Nephrol 26:177–187

    PubMed  Google Scholar 

  11. Honda K, Oda H (2005) Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 25:S19–S29

    PubMed  Google Scholar 

  12. Margetts PJ, Kolb M, Yu L et al (2002) Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 160:2285–2294

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Trigka K, Dousdampanis P, Chu M et al (2011) Encapsulating peritoneal sclerosis: a single-center experience and review of the literature. Int Urol Nephrol 43:519–526

    Article  PubMed  Google Scholar 

  14. Giordano A, Romano S, Mallardo M et al (2008) FK506 can activate transforming growth factor beta signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc Res 79:519–526

    Article  CAS  PubMed  Google Scholar 

  15. Khanna A, Plummer M, Bromberek C et al (2002) Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 62:2257–2263

    Article  CAS  PubMed  Google Scholar 

  16. Van Westrhenen R, Aten J, Hajji N et al (2007) Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif 25:466–472

    Article  PubMed  Google Scholar 

  17. Duman S, Bozkurt D, Sipahi S et al (2008) Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model. Adv Perit Dial 24:104–110

    CAS  PubMed  Google Scholar 

  18. Ceri M, Unverdi S, Dogan M et al (2012) Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model. Int Urol Nephrol 44:977–982

    Article  CAS  PubMed  Google Scholar 

  19. Da Silva N, Rocha S, Rocha L et al (2012) Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient. Pediatr Nephrol 27:1583–1588

    Article  PubMed  Google Scholar 

  20. Huddam B, Azak A, Kocak G et al (2012) Additive effectiveness of everolimus plus tamoxifen therapy in treatment of encapsulating peritoneal sclerosis. Ren Fail 34:387–389

    Article  CAS  PubMed  Google Scholar 

  21. Sud R, Garry L, Spicer ST et al (2014) A role for everolimus in post transplant encapsulating peritoneal sclerosis: first case report. Nephrology (Carlton) 19:27–30

    Article  Google Scholar 

  22. Frasca GM, D’Arezzo M, Ricciatti AM et al (2014) m-TOR inhibitors may be useful in the treatment of encapsulating peritoneal sclerosis (EPS). J Nephrol 27:587–590

    Article  PubMed  Google Scholar 

  23. De Freitas D, Jordaan A, Williams R et al (2008) Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int 28:271–276

    PubMed  Google Scholar 

  24. Eltoum MA, Wright S, Atchley J et al (2006) Four consecutive cases of peritoneal dialysis related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 26:203–206

    CAS  PubMed  Google Scholar 

  25. Thirunavukarasu T, Saxena R, Anijeet H et al (2007) Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature. Ren Fail 29:775–776

    Article  CAS  PubMed  Google Scholar 

  26. Gupta S, Woodrow G (2007) Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen. Clin Nephrol 68:125–129

    Article  CAS  PubMed  Google Scholar 

  27. Mohamed AO, Kamar N, Nogier MB et al (2009) Tamoxifen therapy in kidney-transplant patients presenting with severe encapsulating peritoneal sclerosis after treatment for acute humoral rejection. Exp Clin Transplant 7:164–167

    PubMed  Google Scholar 

  28. Korte MR, Fieren MW, Sampimon DE et al (2011) Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 26:691–697

    Article  CAS  PubMed  Google Scholar 

  29. Evrenkaya TR, Atasoyu EM, Unver S et al (2004) Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 19:2423–2424

    Article  PubMed  Google Scholar 

  30. Moustafellos P, Hadjianastassiou V, Roy D et al (2006) Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc 38:2913–2914

    Article  CAS  PubMed  Google Scholar 

  31. Garosi G, Oreopoulos DG (2009) No need for an ‘‘expiry date’’ in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis. Int Urol Nephrol 41:903–907

    Article  PubMed  Google Scholar 

  32. Junor BJR, McMillan MA (1993) Immunosuppression in sclerosing peritonitis. Adv Perit Dial 9:187–189

    CAS  PubMed  Google Scholar 

  33. Lafrance JP, Letourneau I, Ouimet D et al (2008) Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 51:e7–e10

    Article  PubMed  Google Scholar 

  34. Mori Y, Matsuo S, Sutoh H et al (1997) A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 30:275–278

    Article  CAS  PubMed  Google Scholar 

  35. Kawanishi H, Kawaguchi Y, Fukui H et al (2004) Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 44:729–737

    Article  PubMed  Google Scholar 

  36. Kawanishi H, Harada Y, Noriyuki T et al (2001) Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 17:200–204

    CAS  PubMed  Google Scholar 

  37. Kawanishi H, Moriishi M (2007) Encapsulating peritoneal sclerosis: prevention and treatment. Perit Dial Int 27:S289–S292

    PubMed  Google Scholar 

  38. Wong CF, Beshir S, Khalil A et al (2005) Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 25:285–287

    PubMed  Google Scholar 

  39. Bozkurt D, Sipahl S, Cetin P et al (2009) Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis? Perit Dial Int 29:S206–S210

    CAS  PubMed  Google Scholar 

  40. Rajani R, Smyth J, Koffman CG et al (2002) Differential effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol Dial Transplant 17:2278–2280

    Article  CAS  PubMed  Google Scholar 

  41. Temple S, Zaltzman J, Perl J (2010) Development of encapsulating peritoneal sclerosis in a renal transplant recipient on sirolimus immunotherapy. Perit Dial Int 30:475–477

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Renal Transplantation Unit “A. Vercellone”, Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, Città della Salute e della Scienza Hospital and University of Torino, Corso Bramante, 88-10126, Turin, Italy

    Maria Messina, Claudia Ariaudo, Alberto Mella, Vincenzo Cantaluppi, Giuseppe P. Segoloni & Luigi Biancone

Authors
  1. Maria Messina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Ariaudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alberto Mella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vincenzo Cantaluppi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuseppe P. Segoloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luigi Biancone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Messina.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Messina, M., Ariaudo, C., Mella, A. et al. mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience. J Nephrol 28, 245–249 (2015). https://doi.org/10.1007/s40620-014-0168-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-014-0168-7

Keywords

Search

Navigation